Why the study?
Does Medtronic-Hall valve replacement provide acceptable clinical outcomes in a Third World population group?
Does Medtronic-Hall valve replacement provide acceptable clinical outcomes in a Third World population group?
Medtronic-Hall valve replacement showed acceptable initial late results in a Third World population group, despite low rates of anticoagulation.
Answers are grounded in this paper and cite their sources.
Supports Medtronic-Hall feasibility despite limited anticoagulation in low-resource settings; hypothesis-generating pending randomized comparisons.
In a twenty-month period, 396 Medtronic-Hall valves were inserted in 341 patients belonging to a Third World population group. Approximately 20% of the patients were given anticoagulants. The total follow-up period was 353 patient years (mean 13 months per patient). Late valve-related mortality was 3.6% patient years (excluding ring leaks) with a valve failure rate (VFR) of 4.0%/patient year. The incidence of thromboembolic complications was 6.8%/patient year while valve thrombosis occurred in 7 patients (2.0%/patient year). Hemolysis was generally subclinical, but 2 patients without ring leaks required transfusion. The initial late results compare favorably with those of St. Jude Medical valve replacement in a similar population group. The supreme test for any substitute heart valve is its successful application in a third world population group because its inadequacies are highlighted by an increased VFR and morbidity.
No takes yet. Share an insight, caveat, or question.
Kinsley et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: